Results 81 to 90 of about 2,655 (208)

Competing treatments for migraine: a headache for decision-makers [PDF]

, 2023
BACKGROUND: Migraine is the world’s second most common disabling disorder, affecting 15% of UK adults and costing the UK over £1.5 billion per year.
Duncan, C, Madan, J, Matharu, M, Mistry, H, Naghdi, S, Underwood, M   +5 more
core  

Linking Photophobia, Sleep Disturbances, and Migraine Chronicity: Evidence From a Retrospective Analysis

Brain and Behavior, Volume 16, Issue 3, March 2026.
This study demonstrated that ictal photophobia was present in 89.8% and interictal photophobia in 93.4% of patients. Sleep disturbances were common, with 44.9% reporting difficulty falling asleep. Network analysis revealed stronger associations between interictal photophobia, daytime sleepiness, and medication overuse in chronic migraine compared to ...
Seden Demirci, Ezgi Uludüz, Sevim Eyüboğlu, Fatma Yardibi, Damla Hazal Sucu, Utku Topbaş, Aynur Özge, Derya Uludüz   +7 more
wiley   +1 more source

Impact of galcanezumab on total pain burden: findings from phase 3 randomized, double-blind, placebo-controlled studies in patients with episodic or chronic migraine (EVOLVE-1, EVOLVE-2, and REGAIN trials)

The Journal of Headache and Pain, 2020
Background Focus on the frequency of migraine pain may undervalue the total burden of migraine as pain duration and severity may present unique, additive burden.
Jessica Ailani, J. Scott Andrews, Mallikarjuna Rettiganti, Robert A. Nicholson   +3 more
doaj   +1 more source

Galcanezumab como opção terapêutica e profilática da migrânea: uma revisão sistemática da literatura [PDF]

, 2020
Introdução migrânea trata-se de uma doença neurológica que acarreta diminuição da qualidade de vida relacionada à saúde (QVRS) e está entre as dez principais causas de incapacidade relacionada à doença no mundo.
Lellis, Caio, Lemos, Luísa, Oliveira, Giovanna de, Oliveira, Maria de, Silva Junior, Weldes, Silva, Ledismar, Silva, Sara   +6 more
core   +2 more sources

Central effects of galcanezumab in migraine: a pilot study on Steady State Visual Evoked Potentials and occipital hemodynamic response in migraine patients

The Journal of Headache and Pain, 2022
Background The discovery of the prominent action of Calcitonin Gene Related Peptide –CGRP- on trigeminal afferents and meningeal vessels, opened a new era in migraine treatment.
Marina de Tommaso, Marianna La Rocca, Silvia Giovanna Quitadamo, Katia Ricci, Giusy Tancredi, Livio Clemente, Eleonora Gentile, Elena Ammendola, Marianna Delussi   +8 more
doaj   +1 more source

Comprehensive assessment of erenumab efficacy in participants with high‐frequency episodic migraine with at least one previously failed preventive treatment: The EMBRACE study

Headache: The Journal of Head and Face Pain, Volume 66, Issue 3, Page 658-671, March 2026.
Abstract Objective To evaluate the effect of erenumab treatment beyond monthly migraine days in patients with high‐frequency episodic migraine who did not respond to at least one previous migraine preventive treatment. Background Reduction in monthly migraine days has been the efficacy standard for migraine preventive treatments; however, it does not ...
Gabriel Paiva da Silva Lima, Renata Rao, Gyöngyi Szabó, Sebastian Szklener, Cristina Tassorelli, Marcin Nastaj, Denise E. Chou, Ani C. Khodavirdi, Mahan Chehrenama, Yineng Zhu, Ajay K. Bhatia, David W. Dodick   +11 more
wiley   +1 more source

Galcanezumab-Induced Myasthenia Gravis-Like Symptoms

Cureus, 2023
Fluctuating weakness affecting the ocular, bulbar, and/or appendicular muscles is characteristic of myasthenia gravis. Autoimmune components and certain drugs have been implicated in the pathophysiology of this disease. I report a case of chronic migraine in which the patient developed symptoms of myasthenia gravis after using galcanezumab, the ...
openaire   +2 more sources

Neuro‐Immune Crosstalk: Molecular Mechanisms, Biological Functions, Diseases, and Therapeutic Targets

MedComm, Volume 7, Issue 2, February 2026.
Neurons, immune cells, and other cellular components within the disease microenvironment (such as stromal cells and tumor cells) constitute a dynamically evolving ecosystem. Neurons directly modulate immune cell activity and inflammatory responses through the release of neurotransmitters (e.g., norepinephrine and CGRP), while also promoting tumor ...
Xin Guo, Hui Liu, Yu‐Jing Song, Jian‐Hua Wang, Danfeng Liu, Zhi‐Wei Zheng, Jia‐Jun Li, Boya Li, An Song, Wei He, Lei‐Lei Yang, Shuo Wang   +11 more
wiley   +1 more source

Loss of Melanoregulin (MREG) Enhances Cathepsin-D Secretion by the Retinal Pigment Epithelium [PDF]

, 2013
Cathepsin-D (Cat-D) is a major proteolytic enzyme in phagocytic cells. In the retinal pigment epithelium (RPE), it is responsible for the daily degradation of photoreceptor outer segments (POSs) to maintain retinal homeostasis.
Boesze-Battaglia, Kathleen, Bragin, Alvina, Frost, Laura S., Lopes, Vanda S., Mitchell, Claire H., Stefano, Frank P., Williams, David S.   +6 more
core   +1 more source

Predicting Pharmacological Treatment Response in Migraine Using AI/ML: A Scoping Review of the Evidence and Future Directions

Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, Volume 46, Issue 2, February 2026.
ABSTRACT The treatment of migraine is hampered by inter‐individual variability, leading to an inefficient “trial and error” approach. Artificial intelligence (AI) and machine learning (ML) offer a path towards precision medicine by predicting therapeutic outcomes.
Martina Giacon, Salvatore Terrazzino
wiley   +1 more source